NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) disclosed in a Form 8-K filed on November 16, 2026, that its Executive Chairman, President, and Chief Executive Officer, Amir F. Heshmatpour, purchased 30,000 shares of common stock on the open market on November 13, 2026.

The filing states that these purchases were made with personal funds, and no shares were issued by the company in connection with the transaction. This latest purchase brings Mr. Heshmatpour’s total open-market share acquisitions in 2026 to 371,000 shares, valued at more than $1.5 million.

According to the company’s press release, since reporting topline Phase 2a results for intranasal NEO100 on August 12, 2026, Mr. Heshmatpour has purchased 291,000 shares for over $1 million. In a statement included in the press release, Mr. Heshmatpour noted that his conviction in the company has grown after witnessing patients receiving investigational NEO100 through a compassionate care program at Burjeel Medical City in Abu Dhabi.

Additionally, the company announced that it has scheduled a Type B End-of-Phase meeting with the U.S. Food and Drug Administration (FDA) for early January 2027. The meeting is intended to seek feedback on a potential accelerated approval pathway for intranasal NEO100 and the design of a proposed Phase 3 confirmatory trial.